FTO promotes innate immunity by controlling NOD1 expression via m

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 20 citations in OpenAlex.

1. AACRNL evolved from virulence factor to epigenetic parasite driving genome expansion in free-living eukaryotes.Nature communications · 2026
   Article
2. FTO O-GlcNAcylation promotes TRIM21-mediated FTO ubiquitination degradation to sustain the negative feedback control of macrophage inflammation.Frontiers in immunology · 2025
   Article
3. The GDF6-FTO axis modulates the innate immune and inflammatory response to human respiratory syncytial virus.iScience · 2024
   Article
4. An arms race between 5'ppp-RNA virus and its alternative recognition receptor MDA5 in RIG-I-lost teleost fish.eLife · 2024
   Article
5. New insights into transcriptome variation during cattle adipocyte adipogenesis by direct RNA sequencing.iScience · 2023
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as